Elexacaftor
Elexacaftor is a medication used in the treatment of cystic fibrosis. It is part of a class of drugs known as CFTR modulators, which help improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in individuals with cystic fibrosis.Elexacaftor is indicated for the treatment of cystic fibrosis in patients aged 12 years and older who have at least one F508del mutation in the CFTR gene. It is typically used in combination with other CFTR modulators such as tezacaftor and ivacaftor.
The standard dosage of elexacaftor for adults and children 12 years and older is usually one tablet (combination with tezacaftor and ivacaftor) taken once daily in the morning and one ivacaftor tablet taken in the evening. The exact dosage and regimen may vary based on the patient's condition and should be determined by a healthcare provider.
Elexacaftor is contraindicated in patients with known hypersensitivity to the drug or its components. It should also be avoided in patients with severe hepatic impairment.
Before starting treatment with elexacaftor, patients should have their liver function assessed. Regular monitoring of liver enzymes is necessary during treatment. Patients with severe renal impairment or moderate hepatic impairment should use the drug with caution. Additionally, patients should be aware of potential interactions with other medications and avoid grapefruit or Seville oranges as they can interact with elexacaftor.
Common side effects of elexacaftor include headache, dizziness, abdominal pain, diarrhea, rash, and elevated liver enzymes. Serious side effects can include liver injury, cataracts, and respiratory symptoms. If patients experience severe side effects, they should seek medical attention.
Elexacaftor may interact with other medications, including strong CYP3A inhibitors or inducers, which can affect its levels in the body. Patients should inform their healthcare provider about all medications they are taking to avoid potential interactions.
